New combo aims to fight liver cancer when first treatment fails
NCT ID NCT07219459
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study tests whether adding visugromab to standard drugs (nivolumab and lenvatinib) can help people with advanced liver cancer that has stopped responding to initial treatment. About 104 adults with liver cancer that cannot be removed by surgery or has spread will receive either the new combination or a placebo plus lenvatinib. The goal is to see if the combination slows cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asst Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, 20162, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität
RECRUITINGFrankfurt, 60590, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.